Royalty Report: Drugs, Drug Discovery, Therapeutic – Collection: 344566


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Drug Discovery
  • Therapeutic
  • Molecular
  • Nerve

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 344566

License Grant
For the Patent and Know-how, the German Licensor grants the exclusive right and license throughout the territory under the Licensors patents and know-how, to research, develop, use, sell, offer for sale, have sold, and import Products and Theranostic Products for all indications, subject to Licensors retained rights to use Vilazodone internally as a reference compound for performing pre-clinical research on other compounds.

For the Resulting Intellectual Property, Licensor grants a worldwide, exclusive right and license, with right to sub license (subject, in the case of Products and Theranostic Products, to same sublicensing terms, to use the Resulting IP and Resulting IP Patents for all purposes, including the research, development, manufacture, marketing and sale of Products, Theranostic Products and Diagnostic Products.

For the Vilazodone manufacturing technology Option. Licensor grants an option to obtain a semi-exclusive, paid-up, license under the Vilazodone manufacturing technology, Licensor Patent rights and Know-how to make and have made Vilazodone and Products for so long as Licensee has a license to the Licensor Patents and Know-how.

License Property
Licensor has substantial know-how and expertise relating to Vilazodone and its manufacture.

Product shall mean any product containing Vilazodone as either the single active ingredient or as one of multiple active ingredients.

Theranostic Product shall mean a home-brew test or FDA or EMEA approved kit or device for detecting genetic markers that are correlated to Vilazodone response in humans.

Field of Use
Vilazodone  is an antidepressant.

Indications identified with this agreement include
— Depressive Disorder, including but not limited to
Minor Depressive Disorder, Recurrent brief depressive disorder, Major Depressive Disorder, Dysthymic Disorder, Adjustment Disorder With Depressed Mood, Adjustment  Disorder With Mixed Anxiety and Depressed Mood, Premenstrual dysphoric disorder, and, Postpsychotic depressive disorder of Schizophrenia.

— Anxiety Disorder, including but not limited to
Panic Disorder, Agoraphobia, Specific Phobia, Social Anxiety Disorder, Obsessive-Compulsive Disorder, Posttraumatic Stress Disorder, Acute Stress Disorder, and,
Generalized Anxiety Disorder.

IPSCIO Record ID: 226310

License Grant
Licensor hereby grants to Licensee, for the Term, an exclusive sublicense under the University Licensed Patents, to make, have made, use, offer to sell, sell, and import Licensed Products in the Field in the Territory.  The grant of this Section includes the right to grant sublicenses subject to prior written approval by Licensor which shall not be unreasonably conditioned, delayed, or withheld provided that such sublicense shall not impair or limit any of Licensor's rights under this Restated Agreement.

Licensor hereby grants to Licensee, for the Term, an exclusive license under the Licensor Know-How, to make, use, offer to sell, sell, and import Licensed Products in the Field in the Territory.  

Licensor hereby grants to Licensee, for the Term, an exclusive sublicense under the University Know-How, to make, use, offer to sell, sell, and import Licensed Products in the Field in the Territory.

Licensor hereby grants to Licensee, for the Term, a non-exclusive sublicense under the Nanosizing Licensed Patents, solely in conjunction with the licenses granted of this Restated Agreement, to make, use, and sell Licensed Products in the Field in the Territory.

License Property
Ganaxolone is a clinical stage product candidate.  The company is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Ganaxolone is currently formulated as an IV, liquid suspension and as a capsule.

Ganaxolone is a synthetic small molecule made through a series of organic chemistry steps starting with commercially available organic chemical raw materials.  Ganaxolone is a high-dose water insoluble compound.

Ganaxolone means 3-alpha-hydroxy-3-beta-methyl 5-alpha-pregnan-20-one.

University Licensed Patents means
U.S. Pat. No. 5,232,917 “Methods, Compositions and Compounds for Allosteric Modulation of the GABA receptor”;
U.S. Pat. No. 5,591,733 “Methods, Compositions and Compounds for Allosteric Modulation of the GABA Receptor by Members of the Androstane and Pregnane Series”;
U.S. Pat. No. 5,208,227 “Method, Compositions, and Compounds for Modulating Brain Excitability”;
U.S. Pat. No. 5,319,115 “Method for making 3a-Hydroxy, 3b-Substituted Pregnanes”;

Nanosizing Licensed Patents means U.S. Provisional Pat. Application No. 60/172,573, filed December 20, 1999; and all U.S. and foreign Patents that claim priority therefrom.

Field of Use
This agreement pertains to the drug industry relating to the treatment of epilepsy and other neuropsychiatric disorders.

“Field” means the diagnosis, prevention and treatment of all diseases, disorders or conditions, other than those diseases, disorders or conditions which are in the Excluded Field. Examples of diseases, disorders, or conditions that are within the Field include psychiatric and stress related disorders (e.g., generalized anxiety, obsessive-compulsive disorders, panic disorders, sleep disorders, depression psychoses, schizophrenia, premenstrual dysphoric disorder, posttraumatic stress disorder, and social isolation), addiction (i.e., alcoholism, benzodiazepine abuse, amphetamine abuse, and cocaine abuse), seizure disorders, disorders involving neurodegeneration and neuronal apoptosis where neuronal protection or neurogenesis provides a functional benefit (e.g., Alzheimer’s disease, pre and post-natal treatment for autism, attention deficit disorder, fragile X syndrome), lysosomal storage disorders, and atherosclerosis.

IPSCIO Record ID: 303332

License Grant
With this agreement, the Licensee now holds a license to certain patents and know-how of Licensor.  The licensed rights are exclusive.
License Property
The patents and know-how of Licensor are relating to lumateperone and other specified compounds.  CAPLYTATM (lumateperone) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults (42mg/day).  CAPLYTA refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults, and lumateperone refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia. Lumateperone is in Phase 3 clinical development as a novel treatment for bipolar depression.
Field of Use
This agreement provides the Company with a portfolio of compounds with potential to be effective treatments for schizophrenia and other therapies for CNS indications such as Tourette's syndrome, Bipolar Disorder, and Obsessive-Compulsive Disorder.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.